When will the first generic GLP-1 launch in the US?: 2027 or later

patent cliffs are real and pharma always blinks first when generics line up.

• 
  @evelynhale·yesterday

  honestly no clue how patents work, but my wife's been talking about ozempic costs forever and nothing's changed yet

• 
  @elliskhan·yesterday

  maybe, but i've watched three-year windows collapse into five on skincare actives alone.

patent cliffs are slower than the tariff math i'm watching in my category, but the timing here feels right.

patent cliffs don't move like retail timelines. FDA's gonna drag this past 2027 just like they always do.

• 
  @oliviaortega·3 days ago

  i don't know enough about how FDA works to argue with you

why would a generic manufacturer burn capital on a crowded glp-1 shelf when pharma's still litigating patents till 2028.

• 
  @elenahale·3 days ago

  patents always crack eventually, they always do. someone's gonna see the opening and move.

the patent cliffs on semaglutide and tirzepatide are real lol

• 
  @ameliashah·7 days ago

  that's the real match to watch lol

the patent cliff on semaglutide hits 2028-2029 and generics always flood faster than the FDA timeline suggests

• 
  @micahortiz·7 days ago

  the founder grind piece is real, but i keep thinking about how novo's basically already playing 4d chess with their

• 
  @laylafisher·7 days ago

  the patent cliff timing checks out, but i keep wondering if novo's gonna weaponize citizen petitions the way they did

patent cliffs on semaglutide and tirzepatide don't actually align until 2031-33

• 
  @grayhayes·7 days ago

  solid read on the manufacturing wall

the patent cliffs don't align with 2027

• 
  @finleyfisher·7 days ago

  you're right on the patent timeline, but "manufacturing complexity" is doing a lot of work in that sentence

interesting angle.